Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine

Renato Lenzi, M. N. Raber, D. Gravel, P. Frost, J. L. Abbruzzese

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m2 of 5-aza-CdR and 75 mg/m2 of cDDP. A response rate of 17% (90% confidence interval (CI) = 0%-37%) was observed in patients with metastatic carcinoma of unknown primary (UPC). The 5-aza-CdR/cDDP combination was safely administered at doses mirroring concentrations that significantly lessen cDDP resistance of human ovarian cancer cells in vitro. While the observed response rate did not warrant further study in UPC, evaluation of this regimen should be considered in patients with cDDP-resistant ovarian cancer.

Original languageEnglish (US)
Pages (from-to)447-450
Number of pages4
JournalInternational Journal of Oncology
Volume6
Issue number2
StatePublished - Jan 1 1995

Fingerprint

decitabine
Ovarian Neoplasms
Cisplatin
Maximum Tolerated Dose
Confidence Intervals
Carcinoma

Keywords

  • 2'-deoxy-5-azacytidine
  • Cisplatin
  • Synergy
  • Unknown primary carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine. / Lenzi, Renato; Raber, M. N.; Gravel, D.; Frost, P.; Abbruzzese, J. L.

In: International Journal of Oncology, Vol. 6, No. 2, 01.01.1995, p. 447-450.

Research output: Contribution to journalArticle

Lenzi, Renato ; Raber, M. N. ; Gravel, D. ; Frost, P. ; Abbruzzese, J. L. / Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine. In: International Journal of Oncology. 1995 ; Vol. 6, No. 2. pp. 447-450.
@article{3831fb5b9af54ce4a6cacee06137730a,
title = "Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine",
abstract = "Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m2 of 5-aza-CdR and 75 mg/m2 of cDDP. A response rate of 17{\%} (90{\%} confidence interval (CI) = 0{\%}-37{\%}) was observed in patients with metastatic carcinoma of unknown primary (UPC). The 5-aza-CdR/cDDP combination was safely administered at doses mirroring concentrations that significantly lessen cDDP resistance of human ovarian cancer cells in vitro. While the observed response rate did not warrant further study in UPC, evaluation of this regimen should be considered in patients with cDDP-resistant ovarian cancer.",
keywords = "2'-deoxy-5-azacytidine, Cisplatin, Synergy, Unknown primary carcinoma",
author = "Renato Lenzi and Raber, {M. N.} and D. Gravel and P. Frost and Abbruzzese, {J. L.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "447--450",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine

AU - Lenzi, Renato

AU - Raber, M. N.

AU - Gravel, D.

AU - Frost, P.

AU - Abbruzzese, J. L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m2 of 5-aza-CdR and 75 mg/m2 of cDDP. A response rate of 17% (90% confidence interval (CI) = 0%-37%) was observed in patients with metastatic carcinoma of unknown primary (UPC). The 5-aza-CdR/cDDP combination was safely administered at doses mirroring concentrations that significantly lessen cDDP resistance of human ovarian cancer cells in vitro. While the observed response rate did not warrant further study in UPC, evaluation of this regimen should be considered in patients with cDDP-resistant ovarian cancer.

AB - Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m2 of 5-aza-CdR and 75 mg/m2 of cDDP. A response rate of 17% (90% confidence interval (CI) = 0%-37%) was observed in patients with metastatic carcinoma of unknown primary (UPC). The 5-aza-CdR/cDDP combination was safely administered at doses mirroring concentrations that significantly lessen cDDP resistance of human ovarian cancer cells in vitro. While the observed response rate did not warrant further study in UPC, evaluation of this regimen should be considered in patients with cDDP-resistant ovarian cancer.

KW - 2'-deoxy-5-azacytidine

KW - Cisplatin

KW - Synergy

KW - Unknown primary carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028837293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028837293&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028837293

VL - 6

SP - 447

EP - 450

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -